Published in Oncotarget on September 22, 2015
The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice. Br J Pharmacol (2016) 0.78
Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit (2016) 0.75
Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells. PLoS One (2017) 0.75
Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A (1985) 7.32
Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A (1997) 4.52
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell (1989) 2.14
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci (2014) 1.74
Pharmacologic therapies for infantile hemangioma: is there a rational basis? Plast Reconstr Surg (2011) 1.54
Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem (2004) 1.51
The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev (2003) 1.43
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res (2013) 1.26
Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.21
Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp60(c-src). J Virol (1999) 1.07
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene (2006) 1.07
Structure, regulation, and pharmacological modulation of PP2A phosphatases. Methods Mol Biol (2013) 1.05
Infantile hemangioma: challenges, new insights, and therapeutic promise. J Craniofac Surg (2009) 1.04
Expression of endoglin (CD105) in cervical cancer. Br J Cancer (2009) 1.01
ATM-dependent dissociation of B55 regulatory subunit from nuclear PP2A in response to ionizing radiation. J Biol Chem (2001) 1.00
Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression. Oncotarget (2015) 0.96
CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene (2011) 0.96
Baicalin reduces the permeability of the blood-brain barrier during hypoxia in vitro by increasing the expression of tight junction proteins in brain microvascular endothelial cells. J Ethnopharmacol (2011) 0.94
PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem (2008) 0.93
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia (2014) 0.93
Dephosphorylation of major sperm protein (MSP) fiber protein 3 by protein phosphatase 2A during cell body retraction in the MSP-based amoeboid motility of Ascaris sperm. Mol Biol Cell (2009) 0.93
Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A. J Biol Chem (2014) 0.92
Development of a new method for isolation and long-term culture of organ-specific blood vascular and lymphatic endothelial cells of the mouse. FEBS J (2008) 0.91
Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol (2006) 0.91
Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J Clin Pathol (2010) 0.89
Infantile haemangioma expresses embryonic stem cell markers. J Clin Pathol (2012) 0.88
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol (2015) 0.87
PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Res (2014) 0.86
Domains necessary for Galpha12 binding and stimulation of protein phosphatase-2A (PP2A): Is Galpha12 a novel regulatory subunit of PP2A? Mol Pharmacol (2007) 0.86
Oral propranolol for exudative retinal detachment in diffuse choroidal hemangioma. Arch Ophthalmol (2011) 0.85
Regulation of cardiovascular connexins by mechanical forces and junctions. Cardiovasc Res (2013) 0.84
RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells. Tumour Biol (2010) 0.82
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
Update on infantile hemangiomas. Semin Perinatol (2013) 0.80
Endoglin is a novel endothelial cell specification gene. Stem Cell Res (2011) 0.80
Visualization of subunit interactions and ternary complexes of protein phosphatase 2A in mammalian cells. PLoS One (2014) 0.80
Inhibition of protein phosphatase-1 and -2A decreases the chemosensitivity of leukemic cells to chemotherapeutic drugs. Cell Signal (2014) 0.79
Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer. Br J Cancer (2014) 0.78
Isolation and characterization of endothelial cells from intramuscular hemangioma. J Orthop Sci (2012) 0.77
Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity. Mol Biol Cell (2014) 0.77
Mice transgenic with SV40-late-promoter-driven Polyomavirus Middle T oncogene exclusively develop hemangiomas. Transgenic Res (2008) 0.76